Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012)
NCT01656395 · Merck Sharp & Dohme LLC · PHASE2 · terminated · last registry update 2018-09-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Merck Sharp & Dohme LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTGDR2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2019-04-05Results posted on the registry: Allergan, Setipiprant + Placebo (NCT02781311)
- 2019-02-08Results posted on the registry: Merck Sharp & Dohme LLC, MK-1029 10 mg + MK-1029 100 mg (NCT01343407)
- 2019-01-25Results posted on the registry: Merck Sharp & Dohme LLC, MK-1029 + Placebo for MK-1029 (NCT01370317)
- 2018-11-23Results posted on the registry: Merck Sharp & Dohme LLC, MK-1029 + Placebo (NCT01624974)
- 2018-09-21Phase 3 first posted: Novartis Pharmaceuticals, Fevipiprant 150 mg + Fevipiprant 450 mg (NCT03681093)
- 2018-08-28Results posted on the registry: Merck Sharp & Dohme LLC, MK-1029 150 mg + MK-1029 Matching-image Placebo (NCT02720081)
- 2018-08-14Phase 3 first posted: Novartis Pharmaceuticals, Placebo once daily + QAW039 150 mg once daily (NCT03629249)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision